Cara Therapeutics (CARA)
(Real Time Quote from BATS)
$0.43 USD
-0.01 (-3.07%)
Updated Jun 14, 2024 11:20 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Cara Therapeutics, Inc. [CARA]
Reports for Purchase
Showing records 41 - 57 ( 57 total )
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Results; Pruritus Pipeline Progressing on Plan
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q17 Results; Pruritus Plans on Track; Pain Played Down; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking Past Pain to Pruritus; Transfer Coverage With a Buy and $22 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CR845: Coming to a Pruritus Near You Ahead of Post-Op Pain Data in 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Oral ''845 for Itch Is Off to the Races With Phase 1 Bioequivalency Cleared
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
This Is Why You Do Phase 2-a Clear Positive Signal Warrants Forging Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IV ''845 Interim Look in Post-Op Pain Says Press On; P2 Oral in OA Pain in Coming Days
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Itching for Pain Data and Just Scratching the Surface of ''845''s Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
''845 Seems Clean as a Whistle on Respiratory AE''s
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
''845 Puts on the Best Itchy and Scratchy Show Yet; Raising Target (Again) to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CR845 Stands on Its Own Merits and Is Very Different Than Trevena''s Oliceridine
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Starting to Get Under Your Skin in Uremic Pruritus; Raise Target to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Start Paying Attention Now....BEFORE the Data Come
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with Buy Rating and $20 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C